Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nventa Biopharmaceuticals has announced positive immunological data from the third cohort of its ongoing Phase I clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, a precursor to cervical cancer.
Subscribe to our email newsletter
HPV 16 E7-specific T-cell responses were elicited in all four subjects in the study’s third cohort following administration of 500mcg of HspE7 and 1,000mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. All T-cell responses represented significant changes from baseline, indicating that the responses were a direct result of treatment with HspE7.
Gregory McKee, president and CEO of Nventa, said: “We continue to be very encouraged with the immunological results from our Phase I HspE7 trial as they demonstrate that administration of HspE7 induces T-cell responses that we believe to be therapeutic. These positive immunological data, along with the safety data analyzed to date, provide a strong foundation for our Phase II trial expected to begin mid-2008.”